Clinical Trials Logo

Unresectable Stage III Melanoma clinical trials

View clinical trials related to Unresectable Stage III Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03353402 Recruiting - Melanoma Stage Iv Clinical Trials

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Start date: November 30, 2017
Phase: Phase 1
Study type: Interventional

Altering the Gut Microbiota of Melanoma Patients Who Failed Immunotherapy Using Fecal Microbiota Transplantation (FMT) From Responding Patients. FMT includes both colonoscopy and stool capsules.

NCT ID: NCT03235245 Active, not recruiting - Stage IV Melanoma Clinical Trials

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

EBIN
Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

NCT ID: NCT01605162 Terminated - Clinical trials for Unresectable Stage III Melanoma

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Start date: May 2012
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide (TMZ) in subjects with wt BRAF Stage IV or unresectable Stage III melanoma with disease progression. Eligible subjects must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST).